Explaining a commercial PGx report and HLA safety before carbamazepine (CASC)

Station instructions (candidate)

You have 7 minutes. Acknowledge fear of severe rash. Explain in plain language that some genetic tests (HLA) help estimate rare but serious carbamazepine skin-reaction risk and can guide whether to avoid that drug, while commercial multi-gene colour charts are only partly evidence-based and do not replace clinical judgement. Offer HLA-informed plan before carbamazepine, alternatives if high-risk allele present, and how CYP results (if present) may refine antidepressant dosing without guaranteeing outcome. Do not promise zero risk. Do not dismiss her report as useless without explaining what parts matter.[1][2][3]

Marking domains

Empathy and agenda setting; accurate plain-language HLA-B*15:02/SJS concept; clear distinction between high-action HLA safety and limited PD/combinatorial claims; shared decision and alternatives; safety-netting for rash; avoids both genetic fatalism and false certainty; collaborative plan with written summary.[1][3][4]

Model communication map

1. Open: thank her for bringing information; shared goals — treat bipolar illness and minimise rare severe drug harms.[1]
2. Validate fear: Stevens-Johnson is rare but serious; wanting genetic information is reasonable.[2]
3. HLA plain language: "One immune gene, HLA-B*15:02, if present, means carbamazepine is much more likely to trigger a dangerous blistering reaction in some people — we can test and usually avoid the drug if it is positive."[1][2]
4. Commercial report: "Colour lists mix strong and weak evidence. Guidelines support using certain liver-enzyme genes for dose choice of some antidepressants, but genes like the serotonin transporter should not alone force a switch. We will not change a good plan only because a box is yellow."[3][4]
5. Plan: arrange HLA testing before first carbamazepine dose (or choose alternative mood strategy now); review any CYP results against recognised tables; continue lithium review, sleep, relapse plan; written alert if high-risk HLA found.[1][4]
6. Safety-net: stop new drug and seek urgent care for blistering rash, mouth/eye sores, fever with widespread rash.[1]
7. Close: questions, summary leaflet, GP/pharmacy communication; no absolute guarantee of benefit or zero side effects — partnership over promises.[5]

Common fails

• Guaranteeing carbamazepine is "100% safe if HLA negative."[1]
• Blindly following the entire commercial red/green list.[3][4]
• Refusing to discuss genetics at all or using unexplained acronyms only.[4]
• Starting carbamazepine today without addressing HLA risk in higher-prevalence ancestry contexts.[1][2]
• Abandoning all medication options out of fear without offering alternatives.[4]